Elucidating the role of carbohydrate determinants in regulating hemostasis: Insights and opportunities

Blood

Volumn 121, Issue 19, 2013, Pages 3801-3810

  Preston, Roger J S ^a,b   Rawley, Orla ^a,c   Gleeson, Eimear M ^a,b   O’Donnell, James S ^a,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLYCAN; PLASMA PROTEIN; EPITOPE; GLYCOPROTEIN;

BLOOD CLOTTING; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REVIEW; THROMBOSIS; BLOOD; CARBOHYDRATE ANALYSIS; CONFORMATION; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

BLOOD COAGULATION; BLOOD PROTEINS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; EPITOPES; GLYCOPROTEINS; HEMOSTASIS; HUMANS;

MLCS; MLOWN;

EID: 84880464142     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-415000     Document Type: Review

References (100)

1. Lauc G, Essafi A, Huffman JE, et al. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1a as a master regulator of plasma protein fucosylation. PLoS Genet. 2010;6(12):e1001256.
2. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126(5):855-867.
3. Weerapana E, Imperiali B. Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology. 2006;16(6): 91R-101R.
4. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 1985;54:631-664.
5. Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem. 2004;73:1019-1049.
6. Kelleher DJ, Kreibich G, Gilmore R. Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell. 1992;69(1): 55-65.
7. Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol. 2011;21(5):576-582.
8. Hebert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell. 1995;81(3): 425-433.
9. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol. 1998;33(3):151-208.
10. Wilson IB, Gavel Y, von Heijne G. Amino acid distributions around O-linked glycosylation sites. Biochem J. 1991;275(Pt 2):529-534.
11. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia. 2009;15(6):1187-1196.
12. Marquette KA, Pittman DD, Kaufman RJ. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem. 1995;270(17): 10297-10303.
13. Pittman DD, Tomkinson KN, Kaufman RJ. Posttranslational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994;269(25):17329-17337.
14. Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998;273(14): 8537-8544.
15. Khoriaty R, Vasievich MP, Ginsburg D. The COPII pathway and hematologic disease. Blood. 2012;120(1):31-38.
16. Zhang B, McGee B, Yamaoka JS, et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood. 2006;107(5):1903-1907.
17. Zhang B, Kaufman RJ, Ginsburg D. LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem. 2005;280(27): 25881-25886.
18. Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet. 2003; 34(2):220-225.
19. Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell. 1998;93(1):61-70.
20. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25(11):3171-3184.
21. Canis K, McKinnon TA, Nowak A, et al. Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012;447(2):217-228.
22. Matsui T, Fujimura Y, Nishida S, Titani K. Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. Blood. 1993; 82(2):663-668.
23. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J. 1989;6(3): 263-270.
24. Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, Laffan M, Dell A. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 2010;8(1):137-145.
25. Lenting PJ, Pegon JN, Christophe OD, Denis CV. Factor VIII and von Willebrand factor-too sweet for their own good. Haemophilia. 2010; 16(Suppl 5):194-199.
26. Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood. 1987; 69(5):1531-1534.
27. Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA. O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood. 2012;120(1): 214-222.
28. Badirou I, Kurdi M, Legendre P, et al. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS ONE. 2012;7(5): e37508.
29. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
30. Berkowitz SD, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood. 1988;72(5):1790-1796.
31. Federici AB, Elder JH, De Marco L, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest. 1984;74(6): 2049-2055.
32. McGrath RT, McKinnon TA, Byrne B, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 2010;115(13): 2666-2673.
33. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1): 33-40.
34. O’Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106(6):1988-1991.
35. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111(6):3042-3049.
36. Krudysz-Amblo J, Jennings ME II, Matthews DE, Mann KG, Butenas S. Differences in the fractional abundances of carbohydrates of natural and recombinant human tissue factor. Biochim Biophys Acta. 2011;1810(4):398-405.
37. Butenas S, Krudysz-Amblo J, Mann KG. Posttranslational modifications and activity of natural and recombinant tissue factor. Thromb Res. 2010;125(Suppl 1):S26-S28.
38. Krudysz-Amblo J, Jennings ME II, Mann KG, Butenas S. Carbohydrates and activity of natural and recombinant tissue factor. J Biol Chem. 2010;285(5):3371-3382.
39. Paborsky LR, Tate KM, Harris RJ, et al. Purification of recombinant human tissue factor. Biochemistry. 1989;28(20):8072-8077.
40. Kothari H, Rao LV, Pendurthi UR. Glycosylation of tissue factor is not essential for its transport or functions. J Thromb Haemost. 2011;9(8): 1511-1520.
41. Inoue K, Morita T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. The role of the carbohydrate moieties in the activation of factor X. Eur J Biochem. 1993;218(1):153-163.
42. Yang L, Manithody C, Rezaie AR. Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. J Thromb Haemost. 2009;7(10):1696-1702.
43. Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. J Biol Chem. 1993;268(5):3048-3051.
44. Guéguen P, Cherel G, Badirou I, Denis CV, Christophe OD. Two residues in the activation peptide domain contribute to the half-life of factor X in vivo. J Thromb Haemost. 2010;8(7): 1651-1653.
45. Kurdi M, Cherel G, Lenting PJ, Denis CV, Christophe OD. Coagulation factor X interaction with macrophages through its N-glycans protects it from a rapid clearance. PLoS ONE. 2012;7(9): e45111.
46. Franzén LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem. 1980;255(11): 5090-5093.
47. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem. 1985;260(1):610-615.
48. Brennan SO, George PM, Jordan RE. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. FEBS Lett. 1987;219(2):431-436.
49. Picard V, Ersdal-Badju E, Bock SC. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity. Biochemistry. 1995;34(26):8433-8440.
50. Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Arterioscler Thromb Vasc Biol. 1996; 16(10):1292-1297.
51. Turk B, Brieditis I, Bock SC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36(22):6682-6691.
52. McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin’s heparin affinity and activity. J Mol Biol. 2003; 326(3):823-833.
53. Miletich JP, Broze GJ Jr. Beta protein C is not glycosylated at asparagine 329. The rate of translation may influence the frequency of usage at asparagine-X-cysteine sites. J Biol Chem. 1990;265(19):11397-11404.
54. Grinnell BW, Walls JD, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem. 1991;266(15): 9778-9785.
55. Ní Ainle F, O’Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, Preston RJ. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem. 2011;286(2):1323-1330.
56. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007; 109(8):3161-3172.
57. Yang L, Bae JS, Manithody C, Rezaie AR. Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem. 2007;282(35): 25493-25500.
58. Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem. 1993;268(28):21130-21136.
59. Kim SW, Ortel TL, Quinn-Allen MA, et al. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry. 1999;38(35):11448-11454.
60. Hoekema L, Nicolaes GA, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry. 1997;36(11): 3331-3335.
61. Miyagi T, Yamaguchi K. Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology. 2012;22(7):880-896.
62. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977;252(15):5538-5546.
63. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002;99(15):10042-10047.
64. Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6):648-655.
65. Lenting PJ, Christophe OD, Guéguen P. The disappearing act of factor VIII. Haemophilia. 2010;16(102):6-15.
66. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3(6):1257-1265.
67. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(7):3540-3545.
68. Jenkins PV, O’Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 2006; 46(10):1836-1844.
69. O’Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116(2):350-356.
70. Sørensen AL, Clausen H, Wandall HH. Carbohydrate clearance receptors in transfusion medicine. Biochim Biophys Acta. 2012;1820(11): 1797-1808.
71. van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, van den Berg HM, Denis CV, Lenting PJ. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712.
72. McRae E, Rawley O, Nel H, et al. A critical role for N- and O-linked carbohydrates in modulating Von Willebrand factor clearance in vivo [abstract]. Blood. 2011;118(21). Abstract 382.
73. Pegon JN, Kurdi M, Casari C, Odouard S, Denis CV, Christophe OD, Lenting PJ. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012;97(12):1855-1863.
74. Saint-Lu N, Oortwijn BD, Pegon JN, et al. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol. 2012;32(4): 894-901.
75. Smith NL, Chen MH, Dehghan A, et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010; 121(12):1382-1392.
76. Hennet T. Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochim Biophys Acta. 2012;1820(9):1306-1317.
77. Young G, Driscoll MC. Coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literature. Am J Hematol. 1999;60(1): 66-69.
78. Van Geet C, Jaeken J, Freson K, Lenaerts T, Arnout J, Vermylen J, Hoylaerts MF. Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications. J Inherit Metab Dis. 2001;24(4): 477-492.
79. Steen M, Norstrøm EA, Tholander AL, et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood. 2004;103(9):3381-3387.
80. Maekawa H, Yamazumi K, Muramatsu S, et al. Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator. J Clin Invest. 1992;90(1):67-76.
81. Maekawa H, Yamazumi K, Muramatsu S, et al. An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem. 1991;266(18):11575-11581.
82. Yamazumi K, Shimura K, Terukina S, Takahashi N, Matsuda M. A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest. 1989;83(5):1590-1597.
83. Hertzberg MS, Facey SL, Hogg PJ. An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood. 1999;94(1):156-163.
84. Bertina RM, Ploos van Amstel HK, van Wijngaarden A, et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood. 1990;76(3): 538-548.
85. Giri TK, Yamazaki T, Sala N, Dahlbäck B, de Frutos PG. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood. 2000; 96(2):523-531.
86. Denis CV, Roberts SJ, Hackeng TM, Lenting PJ. In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism. Arterioscler Thromb Vasc Biol. 2005;25(10):2209-2215.
87. Klausen NK, Bayne S, Palm L. Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry. Mol Biotechnol. 1998; 9(3):195-204.
88. Seested T, Nielsen HM, Christensen EI, Appa RS. The unsialylated subpopulation of recombinant activated factor VII binds to the asialo-glycoprotein receptor (ASGPR) on primary rat hepatocytes. Thromb Haemost. 2010;104(6):1166-1173.
89. Hironaka T, Furukawa K, Esmon PC, et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem. 1992;267(12): 8012-8020.
90. Medzihradszky KF, Besman MJ, Burlingame AL. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem. 1997;69(19): 3986-3994.
91. Dasgupta S, Navarrete AM, Bayry J, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD41 T lymphocytes. Proc Natl Acad Sci USA. 2007; 104(21):8965-8970.
92. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 2012;120(4):720-727.
93. Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell WR. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem. 1988; 263(29):15056-15063.
94. Sugo T, Nakamikawa C, Takano H, et al. Fibrinogen Niigata with impaired fibrin assembly: an inherited dysfibrinogen with a Bbeta Asn-160 to Ser substitution associated with extra glycosylation at Bbeta Asn-158. Blood. 1999; 94(11):3806-3813.
95. Brennan SO, Loreth RM, George PM. Oligosaccharide configuration of fibrinogen Kaiserslautern: electrospray ionisation analysis of intact gamma chains. Thromb Haemost. 1998; 80(2):263-265.
96. Bjoern S, Foster DC, Thim L, et al. Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. J Biol Chem. 1991;266(17):11051-11057.
97. Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol. 2012;129(2):501-509.
98. McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, Lane DA, Laffan MA. Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood. 2010;116(4):640-648.
99. Brennan SO, Borg JY, George PM, Soria C, Soria J, Caen J, Carrell RW. New carbohydrate site in mutant antithrombin (7 Ile——Asn) with decreased heparin affinity. FEBS Lett. 1988; 237(1-2):118-122.
100. Fitches AC, Lewandowski K, Olds RJ. Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency. Thromb Haemost. 2001;86(4):1023-1027.